PFEIFFER GARY M sold $292K of DGX
PFEIFFER GARY M sold 1,203 shares of QUEST DIAGNOSTICS INC (DGX) at $243.00 ($0.29M total) on 2026-10-26 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director's sale, especially via a 10b5‑1 plan, can be interpreted as a lack of confidence, prompting short‑term price pressure.
Market read
The filing provides fresh, primary‑source data on insider activity, offering a modest trading signal for DGX.
What to watch
Potential upcoming earnings or strategic announcements could offset the negative signal from the sale.
Background
Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.
Ticker impact
Director Gary M. Pfeiffer sold 1,203 shares of Quest Diagnostics for $292,329 via a 10b5-1 plan, reducing his holdings to 29,802 shares.
likely modest downward pressure as the market prices in the insider sale
Form 4 filings are primary source disclosures; a director sale, even modest, can trigger short‑term selling pressure.
Market effects
Minimal impact on the healthcare diagnostics sector; the sale is company‑specific.
No notable regional effect; limited to investors tracking Quest Diagnostics.
Negligible on a global scale; only relevant to DGX shareholders.
Counterpoint
The sale may be routine under a pre‑arranged 10b5‑1 plan and not indicative of future performance.
Key entities
- CompanyQuest Diagnostics Inc.
Provider of diagnostic testing services, ticker DGX.
- IndividualGary M. Pfeiffer
Director of Quest Diagnostics who executed the sale.


